Literature DB >> 23067217

Altered expression of ezrin, E-Cadherin and β-Catenin in cervical neoplasia.

E Auvinen1, O Carpen, T Korpela, M Ronty, A Vaheri, J Tarkkanen.   

Abstract

High-grade cervical squamous intraepithelial lesions (CIN) as well as squamous cell carcinoma and adenocarcinoma of the cervix are associated with persistent high-risk human papillomavirus (HPV) infection. A number of cellular events play a role in HPV pathogenesis and in the development of cervical lesions, including alterations in cell adhesion and motility. The crucial plasma membrane - cytoskeleton linker protein ezrin of the Ezrin-Radixin-Moesin (ERM) protein family is involved in the regulation of cell morphology, cell adhesion and invasion. Based on our previous work on ERM proteins we sought out to study the expression of ezrin in cervical premalignant lesions. We also studied the expression of E-cadherin and β-catenin, which play an important role in epithelial cell adhesion. We observed intensifying expression of ezrin along with progressing grade of neoplasia. Ezrin staining was found to colocalize with p16 staining in high-risk HPV associated lesions. Expression of E-cadherin and β-catenin was found to be altered along with the severity of the lesion, similar to ezrin. Enhanced expression of ezrin in cervical HPV associated lesions suggests a role in the development of cervical neoplasia and cancer. Further clinical evaluation should reveal the feasibility of ezrin as a biomarker for the progression of cervical lesions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23067217     DOI: 10.4149/neo_2013_008

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  8 in total

1.  Expression of E-cadherin in oral lichen planus.

Authors:  Yong DU; Haobo Li
Journal:  Exp Ther Med       Date:  2015-07-23       Impact factor: 2.447

2.  Photon-induced cell migration and integrin expression promoted by DNA integration of HPV16 genome.

Authors:  Stefan Rieken; Florian Simon; Daniel Habermehl; Jan Oliver Dittmar; Stephanie E Combs; Klaus Weber; Jürgen Debus; Katja Lindel
Journal:  Strahlenther Onkol       Date:  2014-03-19       Impact factor: 3.621

Review 3.  Progress in immunocytochemical staining for cervical cancer screening.

Authors:  Hengzi Sun; Keng Shen; Dongyan Cao
Journal:  Cancer Manag Res       Date:  2019-02-22       Impact factor: 3.989

4.  Increased cycling cell numbers and stem cell associated proteins as potential biomarkers for high grade human papillomavirus+ve pre-neoplastic cervical disease.

Authors:  Maurice Canham; Chara Charsou; June Stewart; Sharon Moncur; Laura Hoodless; Ramya Bhatia; Duanduan Cong; Heather Cubie; Camille Busby-Earle; Alistair Williams; Victoria McLoughlin; John D M Campbell; Kate Cuschieri; Sarah Howie
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

5.  High expression of ezrin predicts poor prognosis in uterine cervical cancer.

Authors:  Jienan Kong; Yan Li; Shuangping Liu; Haidan Jin; Yongjun Shang; Chengshi Quan; Yulin Li; Zhenhua Lin
Journal:  BMC Cancer       Date:  2013-11-04       Impact factor: 4.430

6.  Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study.

Authors:  Astride Audirac-Chalifour; Kirvis Torres-Poveda; Margarita Bahena-Román; Juan Téllez-Sosa; Jesús Martínez-Barnetche; Bernardo Cortina-Ceballos; Guillermina López-Estrada; Karina Delgado-Romero; Ana I Burguete-García; David Cantú; Alejandro García-Carrancá; Vicente Madrid-Marina
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

7.  Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition.

Authors:  Jienan Kong; Chunchan Di; Junjie Piao; Jie Sun; Longzhe Han; Liyan Chen; Guanghai Yan; Zhenhua Lin
Journal:  Oncotarget       Date:  2016-04-12

8.  Ezrin and E-cadherin expression profile in cervical cytology: a prognostic marker for tumor progression in cervical cancer.

Authors:  Ana E Zacapala-Gómez; Napoleón Navarro-Tito; Luz Del C Alarcón-Romero; Carlos Ortuño-Pineda; Berenice Illades-Aguiar; Eduardo Castañeda-Saucedo; Julio Ortiz-Ortiz; Olga L Garibay-Cerdenares; Marco A Jiménez-López; Miguel A Mendoza-Catalán
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.